Evidence map›Paper›PMID 28535817›Full record

Trial reportStem cell research & therapy2017

Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients.

Atieh Makhlough, Soroosh Shekarchian, Reza Moghadasali, Behzad Einollahi, Seyedeh Esmat Hosseini, Neda Jaroughi, Tina Bolurieh, Hossein Baharvand, Nasser Aghdami

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02166489 (Evaluation the Effect of Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease), which is not on this map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02166489 phase1completednot on this map

Evaluation the Effect of Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

TypeinterventionalSponsorRoyan InstituteRan2014 to 2016Enrolled6ConditionsChronic Renal Failure, Polycystic Kidney DiseaseArmsIntravenous injection autologous mesenchymal stem cells
3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Chronic Kidney Disease: Challenges in Translational Medicine.Methods in molecular biology (Clifton, N.J.) · 2023
    Review
  13. Review
  14. Review
  15. Regenerative medicine applications: An overview of clinical trials.Frontiers in bioengineering and biotechnology · 2022
    Review
  16. Mesenchymal stem cells: A new therapeutic tool for chronic kidney disease.Frontiers in cell and developmental biology · 2022
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Atieh MakhloughDepartment of Nephrology, Molecular and Cell Biology Research Center, Sari University of Medical Sciences, Sari, Iran.
Soroosh ShekarchianDepartment of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Reza MoghadasaliDepartment of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Behzad EinollahiNephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Baqiyatallah Hospital, Tehran, Iran.
Seyedeh Esmat HosseiniDepartment of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Neda JaroughiDepartment of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Tina BoluriehDepartment of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Hossein BaharvandDepartment of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Nasser AghdamiDepartment of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. nasser.aghdami@royaninstitute.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutosomal dominant polycystic kidney disease (ADPKD) is a genetic ciliopathy disease characterized by progressive formation and enlargement of cysts in multiple organs. The kidneys are particularly affected and patients may eventually develop end-stage renal disease (ESRD). We hypothesize that bone marrow mesenchymal stromal cells (BMMSCs) are renotropic and may improve kidney function via anti-apoptotic, anti-fibrotic, and anti-inflammatory effects. In this study, we aim to assess the safety and tolerability of a BMMSC infusion in ADPKD patients.

methodsWe performed a single-arm phase I clinical trial with a 12-month follow-up. This study enrolled six eligible ADPKD patients with an estimated glomerular filtration rate (eGFR) of 25-60 ml/min/1.73 m

resultsThere were no patients lost to follow-up. We observed no cell-related adverse events (AE) and serious adverse events (SAE) after 12 months of follow-up. The mean eGFR value of 33.8 ± 5.3 ml/min/1.73 m

conclusionsThis trial demonstrated the safety and tolerability of an intravenous transplantation of autologous BMMSCs. BMMSC efficacy in ADPKD patients should be investigated in a randomized placebo-controlled trial with a larger population, which we intend to perform.

trial registrationClinicalTrials.gov, NCT02166489 . Registered on June 14, 2014.

Indexed as

AdultBlood PressureBone Marrow CellsCreatinineDemographyEndpoint DeterminationFemaleFollow-Up StudiesGlomerular Filtration RateHumansKidneyMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiddle AgedPolycystic Kidney, Autosomal DominantCreatinineAutosomal dominant polycystic kidney diseaseBone marrow mesenchymal stromal cellsChronic kidney disease

Identifiers

PMID28535817
PMCPMC5442691

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.